Core Components A and B of this program are designed to provide flexible, coordinated support services to all five projects in this program. Core Component A consists of cytogenetics and tissue culture support services. Core Component B comprises all support services, other than cytogenetics and tissue culture, for the program and includes scientific administration support, secretarial support, bioengineering, biostatistical services, clinical coordination and field work, an external advisory group and a cancer research seminar series. The roles of the support services in Core Component B are three-fold. First, Core Component B will provide scientific administrative and secretarial support services to the program. Second, Core Component B will supply technical support services in the areas of bioengineering, biostatistics and clinical coordination/field work. The bioengineer will design, improve and build devices for enhanced pulsed field gradient gel electrophoresis that are critical to Project 2 and be responsible for the maintenance, modification and repair of equipment for all projects in this program. The biostatistician will serve on a consultant basis in the 01 year and on a full-time basis in the 02 and subsequent years to provide support in fragile site segregation and linkage analysis for Project 1 in and data management for Projects 1 and 3-5. The clinical coordination/field work support will be provided by a genetic counselor who will contact patients, families, clinics, hospitals and doctors and plan and participate in field trips to obtain specimens. Third, Core Component B will provide extramural administrative and scientific advice for cancer research stimulation. A three-person External Advisory Committee will give critical evaluation and counsel to the program. A Cancer Research Seminar Series will bring extramural investigators to the Southwest Biomedial Research Institute on a regular quarterly basis to effectively reduce scientific isolation, increase interaction between program staff and extramural investigators and promote discussion of the latest developments in techniques, findings and concepts in cancer research. All aspects of Core Component B are designed to give support to the program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA041124-02
Application #
3093860
Study Section
Cancer Therapeutics Program Project Review Committee (CTR)
Project Start
1986-05-05
Project End
1989-04-30
Budget Start
1987-05-01
Budget End
1988-04-30
Support Year
2
Fiscal Year
1987
Total Cost
Indirect Cost
Name
Southwest Biomedical Research Institute
Department
Type
DUNS #
City
Scottsdale
State
AZ
Country
United States
Zip Code
85251
Hecht, F; Hecht, B K (1990) Cancer in ataxia-telangiectasia patients. Cancer Genet Cytogenet 46:9-19
Sreekantaiah, C; Baer, M R; Morgan, S et al. (1990) Trisomy/tetrasomy 13 in seven cases of acute leukemia. Leukemia 4:781-5
Hansen, M F; Morgan, R; Sandberg, A A et al. (1990) Structural alterations at the putative retinoblastoma locus in some human leukemias and preleukemia. Cancer Genet Cytogenet 49:15-23
Cannizzaro, L A; Madaule, P; Hecht, F et al. (1990) Chromosome localization of human ARH genes, a ras-related gene family. Genomics 6:197-203
Walter, T A; Morgan, R; Ondreyco, S et al. (1990) Apparent duplication of inv(3)(q21q26) in one of five cases with inv (3) in myelodysplastic syndromes and acute leukemia. Am J Hematol 33:210-4
Hecht, F; Ramesh, K H; Lockwood, D H (1990) A guide to fragile sites on human chromosomes. Cancer Genet Cytogenet 44:37-45
Morgan, R; Smith, S D; Hecht, B K et al. (1989) Lack of involvement of the c-fms and N-myc genes by chromosomal translocation t(2;5)(p23;q35) common to malignancies with features of so-called malignant histiocytosis. Blood 73:2155-64
Lockwood, D H; Farrier, A; Hecht, F et al. (1989) Not all chromosome imbalance resulting from the 11q;22q translocation is due to 3:1 segregation in first meiosis. Hum Genet 83:287-8
Cogswell, P C; Morgan, R; Dunn, M et al. (1989) Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelogenous leukemia. Blood 74:2629-33
Gemmill, R M; Coyle-Morris, J; Ware-Uribe, L et al. (1989) A 1.5-megabase restriction map surrounding MYC does not include the translocation breakpoint in familial renal cell carcinoma. Genomics 4:28-35

Showing the most recent 10 out of 41 publications